Retina

Scientists at Medical College of Georgia demonstrated in their animal model of retinopathy of prematurity that the small molecule K604, which is being explored in cancer and Alzheimer’s, can block the development of leaky, obstructive blood vessels in the retina, tamp down inflammation and enable more normal blood vessel growth

RGC replacement represents a more formidable challenge.

Ram Kannan, PhD, FARVO, principal investigator and adjunct professor of Ophthalmology at David Geffen School of Medicine, UCLA, Doheny Eye Institute, made a pair of presentations at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans. He offers some of the highlights in a conversation with Ophthalmology Times.

Geographic atrophy is now a major research target.

According to the company, TSN-201 leverages AAV capsid that spreads laterally beyond subretinal injection site to facilitate safe delivery of RS1 to photoreceptors in the central retina/fovea.

The presentations highlighted the Clearside Biomedical’s efforts in suprachoroidal delivery of agents to the back of the eye.

The UCL-Moorfields team have developed a deep learning AI model to screen for ROP, which was trained on a sample of 7,414 images of the eyes of 1,370 newborns who had been admitted to the Homerton Hospital, London, and assessed for ROP by ophthalmologists.

In a presentation at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, Kiora Pharmaceuticals showed its investigational drug has the potential to restore light perception in patients who are blind or living with ultra-low vision due to retinitis pigmentosa.

Ophthalmology Times® talked with Michael Ip, MD, about the 5 year follow-up of the original SCORE2 dataset from the NIH-sponsored clinical trial.at this year's ARVO meeting.

Post-hoc analyses from four Phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in wet age-related macular degeneration and diabetic macular edema.

Dr Edmund Arthur shares his research on the early detection of diabetic retinopathy in underserved communities at this year's ARVO meeting.

Ophthalmology Times® talked with Edmund Arthur, OD, PhD, FAAO, about his research on the early detection of diabetic retinopathy in underserved communities at this year's ARVO meeting.

Ophthalmology Times® talked with Jay Barth, MD, about the work at Ascidian Therapeutics and their research into developing a new way to administer gene therapy at this year's ARVO meeting.

Dr T.Y. Alvin Liu talks about predictive AI and its uses in ophthalmology and screening of the eyes at this year's ARVO meeting.

Dr Caroline Baumal talks about Apellis' presentations focusing on visual function, imaging and artificial intelligence at this year's ARVO meeting.

Hydrogen water intake improved retinal blood flow (RBF) dysregulation in response to flicker stimulation and systemic hyperoxia in type 2 diabetic mice.

Thomas V. Johnson, MD, PhD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation at this year's ARVO meeting on retinal engineering and RGC replacement.

Japanese investigators have found an ocular biomarker of cardiovascular diseases.

Former smokers were at higher risk of having to undergo surgery for TED in a recent study, but the risk was lower than that associated with current smoking.

A recent study aimed to set the record straight on the occurrence of retinal vein occlusions (RVOs) following messenger RNA COVID-19 vaccinations.

AVA-Net is a deep-learning network developed by scientists from the University of Illinois at Chicago.

Reducing treatment burden, finding something other than a shot a month is key.

During a presentation at the Vit-Buckle Society meeting in Las Vegas, Sally S. Ong, MD, highlighted a new study of patients who underwent primary repair of uncomplicated RRDs at the Wilmer Eye Institute to examine the baseline, surgical and postoperative characteristics that affect best-corrected VA outcomes.

Dr Ong and colleagues undertook a retrospective study of patients who underwent primary repair of uncomplicated RRDs at the Wilmer Eye Institute to examine the baseline, surgical, and postoperative characteristics that affect best-corrected VA (BCVA) outcomes.

The programme includes thousands of poster and paper presentations by up-and-coming vision scientists and world leaders in their respective subspecialties.